FOXO4-DRI
A D-retro-inverso peptide that selectively destroys senescent 'zombie cells' by disrupting the FOXO4-p53 interaction that keeps these cells alive. One of the first true senolytic peptides, designed to clear the dysfunctional cells that accumulate with aging and drive chronic inflammation (the 'senescence-associated secretory phenotype'). Demonstrated rejuvenating effects in aged mice but remains highly experimental for human use.
Half-Life
Extended (hours to days; D-amino acid configuration resists protease degradation)
Half-Life Calculator →Typical Dosage
Research only: 5-10 mg/kg in mouse studies (intraperitoneal). No established human dosing protocol. Very expensive and extremely limited availability.
Administration
Subcutaneous injection (research)
Mechanism of Action
FOXO4-DRI is a D-retro-inverso (DRI) peptide — a peptide composed entirely of D-amino acids (mirror image of natural L-amino acids) assembled in reverse sequence order. This DRI modification makes the peptide virtually invisible to cellular proteases (which have evolved to cleave L-amino acid peptide bonds), dramatically extending its biological half-life while preserving the spatial orientation of key amino acid side chains needed for target interaction.
The target is the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. Cellular senescence is a state of permanent cell cycle arrest triggered by DNA damage, oncogene activation, or telomere shortening. Senescent cells would normally undergo p53-mediated apoptosis (programmed cell death), but they evade this fate through a survival mechanism: the transcription factor FOXO4 is selectively upregulated in senescent cells and physically binds to p53, sequestering it in PML (promyelocytic leukemia) nuclear bodies. This binding prevents p53 from activating its pro-apoptotic transcriptional program (PUMA, BAX, NOXA), keeping the damaged cell alive.
FOXO4-DRI competitively disrupts this interaction by mimicking the FOXO4 binding interface for p53 but without the nuclear body-localizing function. When FOXO4-DRI competes p53 away from endogenous FOXO4, liberated p53 can access its apoptotic target genes, triggering mitochondrial outer membrane permeabilization and caspase activation — selectively killing the senescent cell. Crucially, non-senescent cells do not depend on FOXO4-p53 interaction for survival (they have intact cell cycle regulation and don't upregulate FOXO4), so they are unaffected by FOXO4-DRI. This selectivity — killing only 'zombie' senescent cells while sparing healthy cells — makes FOXO4-DRI a true senolytic agent. In the original 2017 Cell publication by de Keizer et al., FOXO4-DRI treatment in aged mice reduced senescent cell burden and restored physical fitness, fur density, and renal function.
Regulatory Status
Not FDA approved. Preclinical only. Published in Cell (2017) by Erasmus University. No clinical trials yet. Available through specialty research suppliers at high cost.
Risks & Safety
Common: unknown (no human trial data). Serious: theoretical risk of clearing beneficial senescent cells involved in wound healing and tumor suppression, potential for impaired tissue repair, unknown effects on cancer surveillance mechanisms. Rare: unknown. Extremely limited human data. Very high cost limits accessibility. Purely experimental compound. Not FDA approved.
Research Papers
3Published: January 14, 2025
Abstract
Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking. FOXO4-DRI, a novel peptide-based intervention, specifically disrupts the interaction between FOXO4 and P53, thereby inducing apoptosis in senescent cells. This study innovatively focuses on the mechanism by which FOXO4-DRI induces apoptosis in senescent endothelial cells, demonstrating that it functions by activating the p53/BCL-2/Caspase-3 signaling pathway to promote selective apoptosis of these cells. FOXO4-DRI significantly improves vascular function and delays vascular aging. These findings not only enrich the molecular understanding of senescent cell clearance but also provide a novel strategy for precise targeting of endothelial cell senescence in therapeutic applications.
Published: June 30, 2025
Abstract
A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI. Here, we solve the solution NMR structural models of the p53 transactivation domain in complex with the FOXO4 forkhead domain and in complex with FOXO4-DRI. Strikingly, we find that the disordered FOXO4-DRI binds to the disordered p53TAD2 and forms a transiently folded complex. In this complex, both, the FOXO4-derived region and the cationic cell permeability peptide contribute to the interaction. Furthermore, we show that p53 phosphorylation enhances the affinity for both FOXO4 and FOXO4-DRI. Summarizing we provide a detailed characterization of the interaction of p53 with FOXO4 and FOXO4-DRI which is the basis for development of p53 inhibitors to treat diseases linked to cellular senescence such as cancers.
Published: February 23, 2025
Abstract
Keloids are pathological scars exhibiting tumour-like aggressiveness and high recurrence rate. Here we find increased proportion of pro-inflammatory and mesenchymal fibroblast subpopulations and senescent fibroblasts, and enhanced expression of senescence-associated secretory phenotype genes using single-cell RNA sequencing analysis, as well as elevated p16 protein and more β-galactosidase-positive cells in keloids. The up-regulated p53-serine15 phosphorylation (p53-pS15) in keloids is identified by phosphospecific protein microarray and western blotting. We further demonstrate that a senolytic FOXO4-D-retro-inverso-isoform peptide (FOXO4-DRI) promotes apoptosis and decreases G0/G1 phase cells in pro-senescence models of keloid organ cultures and fibroblasts, accompanied with p53-pS15 nuclear exclusion. Our study indicates that upregulation of p53-pS15 and p16 maintains a persistent senescent microenvironment to promote cell cycle arrest and apoptosis resistance in keloid fibroblasts. FOXO4-DRI shows potential as a treatment targeting the senescence and apoptosis resistance, and holds promise as an approach to prevent the aggressiveness and relapse of keloids.
Related Peptides
AEDG Peptide
A tetrapeptide (Ala-Glu-Asp-Gly) identical to Epithalon's core active sequence — effectively the same compound. Studied for telomerase activation and pineal gland regulation, promoting melatonin production and potentially slowing cellular aging through telomere maintenance. Part of the Khavinson bioregulator peptide family developed at the Institute of Bioregulation and Gerontology in St. Petersburg.
CJC-1295 (no DAC)
A synthetic GHRH analogue (also called Mod GRF 1-29) consisting of the first 29 amino acids of native GHRH with four amino acid substitutions for increased enzymatic stability. Stimulates natural, pulsatile growth hormone release while preserving the body's somatostatin feedback regulation. One of the most commonly prescribed GH peptides, often combined with Ipamorelin for synergistic effects.
CJC-1295 + Ipamorelin
The most commonly prescribed peptide combination in anti-aging and regenerative medicine. Pairs the GHRH analogue CJC-1295 (Mod GRF 1-29) with the selective ghrelin-mimetic Ipamorelin for synergistic, pulsatile growth hormone release. Exploits two complementary signaling pathways — cAMP (GHRH) and calcium/PLC (ghrelin receptor) — to amplify GH pulses while maintaining minimal side effects.
CJC-1295 with DAC
CJC-1295 with Drug Affinity Complex — the same core GHRH analogue as Mod GRF 1-29 but with a reactive succinimide linker that covalently binds to circulating albumin after injection. This albumin binding dramatically extends the half-life from 30 minutes to nearly a week, allowing weekly dosing. Produces sustained rather than pulsatile GH elevation, which some practitioners consider less physiological.